HALO•November 20, 2026 at 4:11 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Halozyme Suffers Legal Setback as German Court Overturns Keytruda SC Injunction

Read source article

What happened

Halozyme's attempt to block Merck's subcutaneous Keytruda in Germany via a preliminary injunction was overturned by a German court. The ruling allows Merck to continue marketing Keytruda SC while the underlying patent dispute proceeds. Halozyme has responded by filing a new patent lawsuit, indicating the legal battle will continue on its merits. The stock declined on the news, reflecting investor concern that ENHANZE's patent enforcement may be weaker than previously assumed. This development aligns with the master report's warning that adverse IP rulings could materially impair ENHANZE economics.

Implication

Investors should closely monitor the full patent litigation in Germany and other jurisdictions, as a negative final ruling could embolden competitors and weaken Halozyme's bargaining power over its ENHANZE platform. While the overturned injunction is a procedural loss, it does not yet equate to patent invalidation; Halozyme could still prevail on technical merits or secure damages. However, the recurring pattern of legal challenges against its core IP, combined with the 2027 composition-of-matter patent expiry, reinforces the master report's cautious stance. Given the stock trades roughly one-third above its DCF estimate, this news adds downside risk rather than opportunity. Until there is clearer evidence that ENHANZE economics will remain intact beyond 2027, a wait-and-see approach remains prudent.

Thesis delta

The German court's decision to overturn the preliminary injunction is a negative development that undermines the assumption of strong ENHANZE IP enforcement against Merck's Keytruda SC. This weakens the bull case that Halozyme could extract significant royalties or damages from Merck and raises the probability of adverse litigation outcomes. Consequently, the risk/reward tilts further negative, supporting the existing WAIT rating and heightening the importance of monitoring the full patent case.

Confidence

medium